首页> 外文期刊>Daruha-yi Giyahi >Regulation of Intestinal GLP-1 and GLUT2 genes underlie hypoglycemia in Desplatsia subericarpa (Bocq)-Fed Wistar Rats
【24h】

Regulation of Intestinal GLP-1 and GLUT2 genes underlie hypoglycemia in Desplatsia subericarpa (Bocq)-Fed Wistar Rats

机译:肠果皮(Bocq)喂养的Wistar大鼠的低血糖是肠道GLP-1和GLUT2基因调控的基础

获取原文
           

摘要

Background & AimIndigenous people of West Africa use the whole-leaf of Desplatsia subericarpa (Bocq) in anti-diabetic soup delicacy. This study was designed to validate the anti-diabetic claims and delineating possible mechanisms. ExperimentalRT-PCR method was used to investigate regulation of intestinal glucose transporter 2 (GLUT2) and glucagon-like peptide-1 (GLP-1), and pancreatic insulin, L-type voltage-gated calcium channel genes. Insulin exocytosis was also monitored using ELISA method. The kidney sample was investigated for biomarkers of injury (kidney injury molecule-1 (KIM-1) and interleukin-1-?2 (IL-1?2)). Results GLP-1 up-regulation, GLUT2 down-regulation and increased insulin exocytosis but not increased insulin gene expression was observed in animals after a 3-day culinary exposure to D. Subericarpa leaves. This mechanism may explain hypoglycemia in streptozotocin-induced diabetes in animals in this study. KIM-1 and IL-1-?2 genes were marked up regulated in normal animals exposed (14-day) to D. Subericarpa. Recommended applications/industries D. Subericarpa whole leaf contains phytochemicals principles with anti-diabetic potency but may be nephrotoxic. Therefore, for clinical use, selective fractionation of active components from the toxic components is desirable.
机译:背景与目的西非土著人将全叶Desplatsia subericarpa(Bocq)用作抗糖尿病汤的美味佳肴。本研究旨在验证抗糖尿病药的主张并描述可能的机制。实验性RT-PCR方法用于研究肠道葡萄糖转运蛋白2(GLUT2)和胰高血糖素样肽-1(GLP-1)以及胰腺胰岛素,L型电压门控钙通道基因的调控。还使用ELISA方法监测胰岛素的胞吐作用。研究了肾脏样品的损伤生物标志物(肾脏损伤分子1(KIM-1)和白细胞介素-1-β2(IL-1β2))。结果在暴露于果皮的三天后,在动物中观察到GLP-1上调,GLUT2下调和胰岛素胞吐增加,但未发现胰岛素基因表达增加。该机制可能解释了这项研究中链脲佐菌素诱发的动物糖尿病中的低血糖症。 KIM-1和IL-1-?2基因在D.Subericarpa暴露(14天)的正常动物中被上调。推荐的应用/行业D.面包皮整个叶子包含具有抗糖尿病功效的植物化学成分,但可能具有肾毒性。因此,对于临床使用,期望从毒性组分中选择性分离活性组分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号